Shikonin: From Biosynthesis and Pharmacological Mechanisms to Translational Safety and Drug Delivery
ChemBioChem · 2026-11-12 · 27 (21)
DOI: 10.1002/cbic.70586 ↗At a glance
Übersichtsarbeit in ChemBioChem, published online on 2026-11-05. Written by Namini Joshi and 6 co-authors. Institution: Plant Biotechnology Laboratory, Department of Biotechnology, Graphic Era Deemed to be University, Uttarakhand, India. Major MEDLINE topics: Naphthoquinones, Drug Delivery Systems. 123 references. The full text is freely available (open access, CC BY 4.0). Funded by: University Grant Commission,Govt of India.
Abstract (original language)
Shikonin (SHK) is a red naphthoquinone produced mainly in the roots of Boraginaceae species and has been investigated for anticancer, anti‐inflammatory, antimicrobial, neuroprotective, cardioprotective, hepatoprotective, and wound‐healing activities. This review critically integrates botanical sources and biosynthesis with pharmacological mechanisms, preclinical evidence, safety, and delivery strategies. Across cancer models, SHK converges on redox imbalance and regulated cell‐death programmes, including apoptosis, cell‐cycle arrest, autophagy, necroptosis, ferroptosis, and immunogenic cell death, while modulating NF‐κB, MAPK, PI3K/Akt, and related signalling networks. However, the evidence is dominated by heterogeneous in vitro experiments and small‐animal studies, with limited pharmacokinetic standardisation, incomplete assessment of selectivity toward diseased versus normal tissues, and almost no robust clinical evaluation. Poor aqueous solubility, chemical and photochemical instability, rapid metabolism, route‐dependent exposure, and a context‐dependent therapeutic window remain central translational barriers. Liposomes, polymeric micelles, nanoparticles, nanogels, nanoemulsions, and ligand‐ or stimulus‐responsive systems can improve dispersion, tissue accumulation, controlled release, and combination therapy; nevertheless, their long‐term safety, manufacturing reproducibility, and comparative advantage over free SHK require rigorous validation. SHK should therefore be regarded as a mechanistically versatile therapeutic lead rather than a clinically established treatment. Translation will depend on exposure–response studies, standardised formulations, clinically relevant models, and well‐designed human trials.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Plant Biotechnology Laboratory, Department of Biotechnology, Graphic Era Deemed to be University, Uttarakhand, India.
- School of Agriculture, Graphic Era Hill University, Dehradun, Uttarakhand, India.
- Department of Chemistry, College of Basic Sciences and Humanities, G.B. Pant University of Agriculture and Technology, U.S. Nagar, Uttarakhand, India.
- Departamente de Química, Instituto Federal de Educação, Ciência e Tecnologia do Pará (IFPA), Redenção, Brazil.
ORCID profiles: Namini Joshi, Prabhakar Semwal, Balwant Rawat, Ravendra Kumar, Mozaniel Santana de Oliveira, Nishant Rai
Funding
- University Grant Commission,Govt of India
Cite
APA
Joshi, N., Semwal, P., Rawat, B., Kumar, R., Oliveira, M. S., Rai, N., & Rawat, J. M. (2026). Shikonin: From Biosynthesis and Pharmacological Mechanisms to Translational Safety and Drug Delivery. ChemBioChem, 27(21). https://doi.org/10.1002/cbic.70586
Vancouver
Joshi N, Semwal P, Rawat B, Kumar R, Oliveira MS, Rai N, et al. Shikonin: From Biosynthesis and Pharmacological Mechanisms to Translational Safety and Drug Delivery. ChemBioChem. 2026;27(21). doi:10.1002/cbic.70586
BibTeX
@article{Joshi2026,
author = {Joshi, Namini and Semwal, Prabhakar and Rawat, Balwant and Kumar, Ravendra and Oliveira, Mozaniel Santana de and Rai, Nishant and Rawat, Janhvi Mishra},
title = {Shikonin: From Biosynthesis and Pharmacological Mechanisms to Translational Safety and Drug Delivery},
journal = {ChemBioChem},
year = {2026},
volume = {27},
number = {21},
doi = {10.1002/cbic.70586}
}
EUVIMED